ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) was founded in 2010 and is headquartered in Singapore with 56 full-time employees. It is a clinical stage biopharmaceutical company focusing on oncology drug research and development, serving the global market Develop new cancer treatments.
ASLAN Pharmaceuticals Limited (ASLN):
In April 2010, ASLAN Pharmaceuticals Pte. Ltd. was incorporated in Singapore. In June 2014, ASLAN Pharmaceuticals Limited was incorporated in the Cayman Islands. Then, the company’s subsidiaries, ASLAN Pharmaceuticals Taiwan Limited, ASLAN Pharmaceuticals Australia Pty Ltd., ASLAN Pharmaceuticals Hong Kong Limited and ASLAN Pharmaceuticals (Shanghai) Co. Ltd. were also registered in November 2013, July 2014, July 2015 and May 2016, respectively.
The research direction of ASLAN Pharmaceuticals Limited is mainly for diseases with high incidence in Asia and rare diseases in the United States and Europe. The company’s Asian development platform aims to help companies accelerate the development of drugs to treat these diseases.
ASLAN Pharmaceuticals’ current 4 product candidates include 3 directions: validated growth pathways for new patients, new immune checkpoints, and new cancer metabolic pathways.
1. ASLAN Pharmaceuticals’ leading product candidate- varlitinib (varlitinib), is a reversible small molecule pan-epidermal growth factor receptor (pan-HER) inhibitor, targeting human epidermal growth factor receptor HER1, HER2 And HER4. Currently, Varlitinib (Varitinib) is undergoing a key global clinical trial study on biliary tract cancer, and the company expects that the study will report topline data in 2019. At present, Varitinib is still in the phase II/III clinical trials for the treatment of gastric cancer. The company expects to report phase II data in the second half of 2018.
2. ASLAN003 (DHODH inhibitor)-an orally effective DHODH inhibitor, may become AML (AML is a cancer of the blood cell line, which is mainly manifested by the rapid growth of abnormal white blood cells formed in the bone marrow and interferes with the production of normal blood cells ) The drug of choice. Obtained product license from Almirall in 2013, and the company has the rights to all non-topical and non-dermatological indications of the candidate product worldwide. Currently, ASLAN Pharmaceuticals is conducting a phase II clinical trial to develop ASLAN003 for the treatment of AML. The company is also exploring other solid tumor types that DHODH may be associated with, such as TNBC and HCC.
3. ASLAN004 (IL-4 and IL-13 receptor inhibitor) ——ASLAN004 is a fully humanized monoclonal antibody that can target IL-13 receptor α1 subunit (IL-13Rα1), and may become Best-in-class therapy. ASLAN004 is currently in the pre-clinical development stage. By targeting IL-13Rα1, ASLAN004 effectively inhibits interleukin 4 (IL-4) and interleukin 13 (IL-13) signaling. IL-4 and IL-13 are the main factors that cause allergic symptoms of atopic dermatitis (such as skin redness and itching) and asthma symptoms (such as shortness of breath, wheezing, and coughing).
4. ASLAN002 -is an effective small molecule inhibitor of RON (IC50 = 1.8nM) and cMET (IC50 = 3.9nM) receptor tyrosine kinases. The first phase study of ASLAN002 showed that it was well tolerated. Currently, Bristol-Myers Squibb has repurchased the rights of ASLAN002 (BMS777607) and is responsible for all development and commercialization activities.
ASLAN Pharmaceuticals Limited (ASLN) investment:
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) submitted its IPO prospectus on 3/26/2018 and listed on Nasdaq on 5/4/2018 with an issue price of US$7.05. It issued 6 million shares and raised US$42.18 million.